JJIJ
FATE icon

Johnson & Johnson Innovation - JJDC’s Fate Therapeutics FATE Stock Holding History

Johnson & Johnson Innovation - JJDC’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$293M Hold
3,379,064
– – 29.98% 1
2021
Q1 		$279M Hold
3,379,064
– – 36.08% 1
2020
Q4 		$307M Hold
3,379,064
– – 39.62% 1
2020
Q3 		$135M Hold
3,379,064
– – 27.18% 2
2020
Q2 		$116M Buy
+3,379,064
New +$101M 22.77% 2

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Johnson & Johnson Innovation - JJDC's FATE Position: Q2 2021 in Review

Johnson & Johnson Innovation - JJDC held its Fate Therapeutics (FATE) position steady in Q2 2021 at 3,379,064 shares worth $293M. The position accounts for 29.98% of the portfolio, ranked #1.

Johnson & Johnson Innovation - JJDC first reported a position in FATE in Q2 2020 and has held it in 5 quarters since. The position peaked at $307M in Q4 2020. 272 funds tracked by Wall St. Rank hold FATE as of Q2 2021.

  • Johnson & Johnson Innovation - JJDC held 3,379,064 shares of Fate Therapeutics worth $293M as of Q2 2021.
  • Johnson & Johnson Innovation - JJDC left its Fate Therapeutics share count unchanged in Q2 2021.
  • Fate Therapeutics made up 29.98% of Johnson & Johnson Innovation - JJDC's portfolio in Q2 2021, its #1 holding.
  • Johnson & Johnson Innovation - JJDC first reported a position in Fate Therapeutics in Q2 2020 and has held it in 5 quarters since.
  • Johnson & Johnson Innovation - JJDC's Fate Therapeutics position peaked at $307M in Q4 2020.
  • 272 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2021.

Based on Johnson & Johnson Innovation - JJDC's 13F filing for Q2 2021, filed 3 Aug 2021.